Co-inhibition of EGFR and NF-κB pathways blocked EGFR inhibition-induced A3B upregulation in oncogenic EGFR-driven NSCLC xenografts (Extended Data Fig. 7c,d). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.